company background image

Acer Therapeutics NasdaqCM:ACER Stock Report

Last Price


Market Cap







07 Aug, 2022


Company Financials +
ACER fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health2/6

ACER Stock Overview

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases.

Acer Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Acer Therapeutics
Historical stock prices
Current Share PriceUS$1.44
52 Week HighUS$3.77
52 Week LowUS$1.16
1 Month Change-5.26%
3 Month Change-22.99%
1 Year Change-44.62%
3 Year Change-39.50%
5 Year Changen/a
Change since IPO-85.66%

Recent News & Updates

Jul 28

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Acer Therapeutics (NASDAQ:ACER) and partner Relief Therapeutics (OTCQB:RLFTF) (OTCQB:RLFTY) on Thursday said the U.S. Food and Drug Administration (FDA) had accepted the companies' resubmission of their new drug application for their ACER-001 treatment for patients with urea cycle disorders. The FDA designated the new drug application (NDA) as a class 2 resubmission and said it would review the application by Jan. 15, 2023, or the so-called Prescription Drug User Fee Act date. Despite the news, ACER stock had fallen 4.2% to $1.37 in premarket trading. The FDA's acceptance of the NDA comes 10 days after ACER and RLFTF resubmitted the application. The NDA had been initially declined by the FDA in June as the agency's field investigator had been unable to complete inspection of ACER's third-party contract packaging manufacturer.

Jul 18

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Newton, Massachusetts-based Acer Therapeutics (NASDAQ:ACER) announced on Monday that the company resubmitted its New Drug Application (NDA) seeking FDA approval of ACER-001 oral suspension for the treatment of patients with urea cycle disorders (UCDs). Also known as sodium phenylbutyrate, ACER-001 is undergoing studies as a treatment for various inborn errors of metabolism such as UCDs. In June, Acer (ACER) announced that the FDA issued a Complete Response Letter (CRL), rejecting the marketing approval of the drug, citing the need for satisfactory inspection of its third-party contract packaging manufacturer. In the resubmission, the company has informed the FDA that the contract manufacturer in question is ready for inspections. In addition to labeling and other standard updates to the original filing, the resubmitted NDA included the nonclinical info that the FDA requested but categorized as “not an approvability issue” in the CRL. A decision on the acceptance of the NDA is expected within 14 calendar days of the submission. Last month, the shares of Acer (ACER) and its partner Relief Therapeutics (OTCQB:RLFTF) fell on the announcement of FDA rejection of ACER-001.

Shareholder Returns

ACERUS PharmaceuticalsUS Market

Return vs Industry: ACER underperformed the US Pharmaceuticals industry which returned 1.9% over the past year.

Return vs Market: ACER underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is ACER's price volatile compared to industry and market?
ACER volatility
ACER Average Weekly Movement13.2%
Pharmaceuticals Industry Average Movement11.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: ACER is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ACER's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

199139Chris Schelling

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist.

Acer Therapeutics Inc. Fundamentals Summary

How do Acer Therapeutics's earnings and revenue compare to its market cap?
ACER fundamental statistics
Market CapUS$22.46m
Earnings (TTM)-US$19.94m
Revenue (TTM)US$360.00k


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACER income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$360.00k
Other ExpensesUS$20.30m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-1.28
Gross Margin100.00%
Net Profit Margin-5,539.36%
Debt/Equity Ratio-130.0%

How did ACER perform over the long term?

See historical performance and comparison